Zacks Research Has Optimistic Outlook of CORT Q2 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research lifted their Q2 2025 EPS estimates for Corcept Therapeutics in a note issued to investors on Wednesday, March 19th. Zacks Research analyst K. Das now forecasts that the biotechnology company will earn $0.37 per share for the quarter, up from their prior estimate of $0.34. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.47 EPS, FY2025 earnings at $1.64 EPS, Q2 2026 earnings at $0.67 EPS, Q3 2026 earnings at $0.82 EPS, Q4 2026 earnings at $0.89 EPS, FY2026 earnings at $2.83 EPS and FY2027 earnings at $3.81 EPS.

CORT has been the topic of a number of other research reports. Canaccord Genuity Group increased their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, January 30th. StockNews.com cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Piper Sandler increased their price target on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $115.00 price target on shares of Corcept Therapeutics in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $99.75.

Corcept Therapeutics Trading Up 1.9 %

NASDAQ:CORT opened at $58.66 on Friday. The company’s 50 day moving average price is $61.49 and its 200-day moving average price is $53.68. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $75.00. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a market cap of $6.19 billion, a price-to-earnings ratio of 46.56 and a beta of 0.61.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business had revenue of $181.89 million during the quarter, compared to analysts’ expectations of $200.12 million.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the transaction, the insider now directly owns 85,318 shares in the company, valued at approximately $4,299,174.02. This trade represents a 18.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph K. Belanoff sold 2,924 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $60.91, for a total transaction of $178,100.84. Following the completion of the transaction, the chief executive officer now owns 3,019,411 shares in the company, valued at $183,912,324.01. The trade was a 0.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 45,627 shares of company stock worth $2,557,674 over the last quarter. Company insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Kestra Investment Management LLC bought a new position in Corcept Therapeutics in the fourth quarter worth approximately $27,000. Canada Pension Plan Investment Board bought a new position in Corcept Therapeutics in the fourth quarter worth approximately $40,000. National Bank of Canada FI bought a new position in Corcept Therapeutics in the fourth quarter worth approximately $42,000. USA Financial Formulas purchased a new stake in shares of Corcept Therapeutics in the fourth quarter worth $54,000. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of Corcept Therapeutics in the fourth quarter worth $58,000. 93.61% of the stock is currently owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.